State of New Jersey Common Pension Fund D Purchases 46,541 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

State of New Jersey Common Pension Fund D increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 236,532 shares of the biopharmaceutical company’s stock after buying an additional 46,541 shares during the period. State of New Jersey Common Pension Fund D owned about 0.08% of Amicus Therapeutics worth $3,356,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new position in Amicus Therapeutics in the 4th quarter worth $1,173,000. Envestnet Asset Management Inc. boosted its holdings in shares of Amicus Therapeutics by 170.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 393,728 shares of the biopharmaceutical company’s stock valued at $4,788,000 after purchasing an additional 248,220 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in shares of Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 3,082 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Amicus Therapeutics by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock valued at $329,924,000 after purchasing an additional 107,456 shares during the last quarter. Finally, MPM Bioimpact LLC boosted its holdings in shares of Amicus Therapeutics by 38.7% during the 3rd quarter. MPM Bioimpact LLC now owns 716,139 shares of the biopharmaceutical company’s stock valued at $8,708,000 after purchasing an additional 200,000 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have commented on FOLD. JPMorgan Chase & Co. dropped their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Thursday, February 29th.

Insider Buying and Selling

In related news, Chairman John F. Crowley sold 31,614 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.81, for a total value of $436,589.34. Following the sale, the chairman now directly owns 697,628 shares of the company’s stock, valued at approximately $9,634,242.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Chairman John F. Crowley sold 31,614 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.81, for a total value of $436,589.34. Following the sale, the chairman now directly owns 697,628 shares of the company’s stock, valued at approximately $9,634,242.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Michael Clark sold 4,427 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $61,978.00. Following the transaction, the insider now directly owns 253,664 shares in the company, valued at $3,551,296. The disclosure for this sale can be found here. Insiders have sold 48,108 shares of company stock valued at $662,605 in the last ninety days. 2.10% of the stock is owned by company insiders.

Amicus Therapeutics Stock Up 1.1 %

Shares of NASDAQ:FOLD opened at $10.28 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42. Amicus Therapeutics, Inc. has a 12 month low of $9.70 and a 12 month high of $14.57. The company has a 50-day moving average price of $11.95 and a 200 day moving average price of $11.99. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -20.16 and a beta of 0.75.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The business had revenue of $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. As a group, equities research analysts predict that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.